Last reviewed · How we verify
Clinician Communication About Sexual Health
NA trial testing iShare in Breast Cancer in 32 participants. Completed in 12 October 2020.
| Lead sponsor | Fox Chase Cancer Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 32 |
| Start date | 7 February 2020 |
| Primary completion | 12 October 2020 |
| Estimated completion | 12 October 2020 |
| Sites | 1 location across United States |
Fox Chase Cancer Center — full company profile →
Eligibility, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Enrollment will be measured through measures of participant enrollment defined as the percent of eligible candidates approached who enroll in the pilot trial.
| Group | Value | 95% CI |
|---|---|---|
| iShare | 96.97 |
Study retention will defined as percentage of enrolled participants who complete all study surveys.
| Group | Value | 95% CI |
|---|---|---|
| iShare | 93.75 |
Intervention completion will defined as percentage of enrolled participants who complete participation in the podcast intervention.
| Group | Value | 95% CI |
|---|---|---|
| iShare | 93.75 |
Acceptability will be measured through the percentage of the sample endorsing 6 primary acceptability items favorably at two time points (1 week and 1 month; satisfaction, informativeness, relevance, ease of listening, likelihood to recommend, likelihood to impact practice).
| Group | Value | 95% CI |
|---|---|---|
| iShare | 80 |
Clinician knowledge about sexual health and communication will be measured using a 10-item scale asking about common sexual problems experienced by breast cancer patients and the most effective ways to communicate with patients about these issues. Knowledge scores range from 0 to 10, with higher scores indicating more knowledge. Knowledge will be reported as the mean of items answered correctly. Positive mean change scores indicate an increase in knowledge over time.
| Group | Value | 95% CI |
|---|---|---|
| iShare | 1.6 | 0.82 – 2.3 |
Clinician self-efficacy about sexual health communication will be measured using a 3-item scale asking about confidence in discussing sexual concerns with patients. Mean scores range from 0-10, with higher scores indicating higher self-efficacy. Positive mean change scores indicate an increase in self-efficacy over time.
| Group | Value | 95% CI |
|---|---|---|
| iShare | 0.76 | 0.29 – 1.2 |
Clinician outcome expectancies for sexual health communication will be measured using a 7-item scale asking about expected positive results in discussing sexual concerns with patients. Mean scores range from 0-10, with higher scores indicating better expected outcomes. Positive mean change scores indicate an increase in outcome expectancies over time.
| Group | Value | 95% CI |
|---|---|---|
| iShare | 0.52 | 0.17 – 0.86 |
Clinician comfort with sexual health communication will be measured using a 7-item scale asking about comfort level in discussing sexual concerns with patients. Mean scores range from 0-10, with higher scores indicating a higher level of comfort. Positive mean change scores indicate an increase in comfort level over time.
| Group | Value | 95% CI |
|---|---|---|
| iShare | 0.80 | 0.46 – 1.14 |
Clinician communication about sexual health will be measured using a 3-item scale asking about recent communication practices around sexual health (initiating conversations, offering information, giving referrals). Mean scores range from 1-5, with higher scores indicating higher amounts of communication. Positive mean change scores indicate an increase in communication behaviors over time.
| Group | Value | 95% CI |
|---|---|---|
| iShare | 0.16 | -0.15 – 0.46 |
The objective of this study is to adapt a previously tested brief intervention aimed at enhancing clinicians communication about sexual health (iSHARE) to a mobile web-based platform showcasing a two-part podcast and to assess the feasibility, acceptability, and preliminary effects of the intervention in breast cancer clinicians.
2 peer-reviewed publications reference this trial (live from Europe PMC):
Verify or expand the search:
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04262219.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing